婴儿痉挛症药物市场规模、份额和成长分析（按疗法、类型、剂量、给药途径、最终用户、分销管道和地区划分）—2026-2033年产业预测

预计到 2024 年，全球婴儿痉挛症治疗市场规模将达到 1.4924 亿美元，到 2025 年将达到 1.5909 亿美元，到 2033 年将达到 2.6528 亿美元，预测期（2026-2033 年）的复合年增长率为 6.6%。

婴儿痉挛症治疗药物的全球市场正经历显着增长，这主要得益于该疾病发病率的上升、人们对婴儿痉挛症作为儿童疾病的认识不断提高，以及政府对研发的大力支持。儿童神经病学基础设施的扩建和药物製剂的进步对于支持治疗方法至关重要。此外，全球儿童神经病学专科服务的快速发展也有助于提高治疗的可近性。先进的脑电图（EEG）、磁振造影（MRI）和基因分析工具等技术进步，提升了婴儿痉挛症的早期诊断能力。儘管公众意识的提高以及政府医疗保健项目和非营利组织的大量资金支持推动了该市场的发展，但高昂的治疗费用、缺乏训练有素的专家、潜在的副作用以及某些地区诊断不足等挑战仍然是限制市场增长的障碍。

推动全球婴儿痉挛症药物市场发展的因素

医学界对婴儿痉挛症的认识不断提高，显着提升了诊断和治疗的速度和准确性。小儿科和全科医生对婴儿痉挛症的症状和严重的了解不断加深，使得疑似病例更快地转诊至专科医生。这种临床关注的提升不仅带来了更即时的治疗性介入，降低了长期神经发育障碍的风险，也促进了婴儿痉挛症专科治疗方法的普及。因此，这一趋势正在推动全球婴儿痉挛症治疗市场的成长。

限制全球婴儿痉挛药物市场的因素

全球婴儿痉挛症治疗市场面临许多挑战，例如促肾上腺皮质激素（ACTH）和Vigabatrin等治疗方法会带来严重的副作用，如肾上腺抑制、视力障碍和免疫抑制。这些不良反应可能导致医护人员和看护者在考虑治疗方案时犹豫不决。此外，缺乏更安全的长期替代疗法加剧了这个问题，可能导致治疗中断或患者放弃治疗。这种犹豫会阻碍婴儿痉挛症的有效治疗，最终影响患者的治疗效果和整体市场成长。

婴儿痉挛症治疗市场的全球趋势

全球婴儿痉挛症药物市场正经历着向精准医疗和基因分析的重大转变，彻底改变了治疗方法。基因检测和次世代定序的日益普及，有助于识别婴儿痉挛症的根本病因，从而实现个人化和标靶化治疗。随着分子诊断技术的进步，其可及性和可负担性不断提高，製药公司正优先开发针对特定突变的标靶治疗。这一趋势不仅有望透过个人化治疗改善患者预后，也凸显了创新治疗方案的潜力，从而推动婴儿痉挛症治疗领域的成长和变革。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

全球婴儿痉挛症治疗市场规模（按疗法和复合年增长率划分）（2026-2033 年）

• 抗惊厥药
• 皮质类固醇
• 其他的

全球婴儿痉挛症治疗市场规模（按类型和复合年增长率划分）（2026-2033 年）

• Vigabatrin
• 促肾上腺皮质激素
• III期临床试验

全球婴儿痉挛症治疗市场规模（按剂量和复合年增长率划分）（2026-2033 年）

• 固态剂型
• 液体

全球婴儿痉挛症治疗市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 口服
• 肠外
• 其他的

全球婴儿痉挛症治疗市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 诊所
• 医院
• 其他的

全球婴儿痉挛症治疗市场规模（按分销管道和复合年增长率划分）（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房

全球婴儿痉挛症治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Amneal Pharmaceuticals LLC（US）
• Cipla（India）
• Endo, Inc.（US）
• H. Lundbeck A/S（Denmark）
• Hetero（India）
• Intas Pharmaceuticals Ltd.（India）
• Jazz Pharmaceuticals, Inc.（Ireland）
• Mallinckrodt（Ireland）
• MSN Laboratories（India）
• Ovid Therapeutics（US）
• SGPharma Pvt. Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Zydus Group（India）
• Merz Therapeutics（US）
• Ionis Pharmaceuticals（US）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Eisai Co., Ltd.（Japan）

结论与建议

Global Infantile Spasms Therapeutics Market size was valued at USD 149.24 Million in 2024 and is poised to grow from USD 159.09 Million in 2025 to USD 265.28 Million by 2033, growing at a CAGR of 6.6% during the forecast period (2026-2033).

The global market for infantile spasms therapeutics is experiencing significant growth driven by an increase in the incidence of the condition, enhanced awareness of pediatric diseases, and robust governmental support for research and development efforts. The proliferation of pediatric neurology infrastructure and advancements in drug formulations are pivotal in bolstering therapeutic adoption. Moreover, the surge in specialized pediatric neurology services worldwide is enhancing access to treatments. Technological advancements such as sophisticated EEG, MRI, and genetic sequencing tools are improving early diagnostic capabilities for infantile spasms. While rising awareness and substantial funding from government healthcare programs and nonprofit organizations support this market, challenges such as high treatment costs, a shortage of trained specialists, potential side effects, and underdiagnosis in certain regions continue to pose barriers to market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infantile Spasms Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infantile Spasms Therapeutics Market Segments Analysis

Global Infantile Spasms Therapeutics Market is segmented by Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Anticonvulsants, Corticosteroids and Others. Based on Type, the market is segmented into Vigabatrin, Adrenocorticotropic Hormone and Phase III. Based on Dosage, the market is segmented into Solid and Liquid. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Clinic, Hospital and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infantile Spasms Therapeutics Market

The increasing awareness within the medical community regarding infantile spasms has significantly improved the speed and accuracy of diagnosis and treatment. Enhanced education among pediatricians and general practitioners about the symptoms and critical nature of these spasms has led to quicker referrals to specialists for suspected cases. This heightened level of clinical attention has resulted in more immediate therapeutic interventions, which not only mitigate the risk of long-term neurodevelopmental impairments but also promote greater utilization of treatments specifically designed for infantile spasms. Consequently, this trend is driving growth in the global market for infantile spasms therapeutics.

Restraints in the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market faces challenges due to the substantial side effects linked with treatments such as ACTH and vigabatrin, which include adrenal suppression, vision impairment, and immune suppression. These adverse effects can create reluctance among healthcare professionals and caregivers when considering treatment options. Furthermore, the lack of safer long-term alternatives exacerbates this issue, potentially leading to discontinuation or avoidance of treatment in some cases. This hesitation can hinder the effective management of infantile spasms, ultimately impacting patient outcomes and the overall growth of the market.

Market Trends of the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market is witnessing a significant shift towards precision medicine and genetic profiling, which is revolutionizing treatment approaches. Increasing utilization of genetic testing and next-generation sequencing facilitates the identification of underlying causes of infantile spasms, enabling personalized and targeted interventions. As advancements in molecular diagnostics enhance accessibility and affordability, pharmaceutical companies are prioritizing the development of mutation-targeted therapies. This trend not only promises improved patient outcomes through tailored treatments but also underscores the potential for innovative therapeutic solutions, driving growth and transformation within the infantile spasms therapeutics landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Infantile Spasms Therapeutics Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Anticonvulsants
• Corticosteroids
• Others

Global Infantile Spasms Therapeutics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Vigabatrin
• Adrenocorticotropic Hormone
• Phase III

Global Infantile Spasms Therapeutics Market Size by Dosage & CAGR (2026-2033)

• Market Overview
• Solid
• Liquid

Global Infantile Spasms Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral
• Others

Global Infantile Spasms Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Clinic
• Hospital
• Others

Global Infantile Spasms Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Infantile Spasms Therapeutics Market Size & CAGR (2026-2033)

• North America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amneal Pharmaceuticals LLC (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals, Inc. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSN Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGPharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merz Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations